Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis

Addiction

Volumn 105, Issue 2, 2010, Pages 311-318

  Vickerman, Peter ^a,b   Hickman, Matthew ^b   May, Margaret ^a   Kretzschmar, Mirjam ^c,d   Wiessing, Lucas ^e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Ecological analysis; Epidemiology; Hepatitis C; HIV; Injecting drug use; Systematic review

Indexed keywords

AFRICA SOUTH OF THE SAHARA; CONFIDENCE INTERVAL; DISEASE TRANSMISSION; EPIDEMIC; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; META ANALYSIS; PREVALENCE; REVIEW; RISK FACTOR; SOUTH AMERICA; SUBSTANCE ABUSE; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; CONFIDENCE INTERVALS; DISEASE OUTBREAKS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE; RISK FACTORS; SOUTH AMERICA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 74249087579     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02759.x     Document Type: Article

References (28)

1. Baggaley R. F., Boily M. C., White R. G., Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006 20 : 805 812.
2. De Carli G., Puro V., Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003 31 : 22 7.
3. Terrault N. A. Sexual activity as a risk factor for hepatitis C. Hepatology 2002 36 : S99 105.
4. Powers K., Poole C., Pettifor A., Cohen M. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008 8 : 553 554.
5. Boily M. C., Baggaley R. F., Wang L., Masse B., White R., Hayes R. et al. Heterosexual risk of HIV-1 infection per sexual act: a systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009 9 : 118 129.
6. Kral A. H., Bluthenthal R. N., Lorvick J., Gee L., Bacchetti P., Edlin B. R. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001 357 : 1397 1401.
7. Strathdee S. A., Galai N., Safaiean M., Celentano D. D., Vlahov D., Johnson L. et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001 161 : 1281 1288.
8. Gibson D. R., Flynn N. M., McCarthy J. J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999 13 : 1807 1818.
9. Gibson D. R., Flynn N., Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001 15 : 1329 1341.
10. van Den Berg C., Smit C., Van Brussel G., Coutinho R. A., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 2007 102 : 1454 1462.
11. Vickerman P., Hickman M., Rhodes T., Watts C. H. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr 2006 42 : 355 361.
12. Des Jarlais D. C., Perlis T., Arasteh K., Torian L. V., Hagan H., Beatrice S. et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005 19 : S20 5.
13. Boily M. C., Pickles M., Vickerman P., Buzdugan R., Isac S., Deering K. N. et al. Using mathematical modelling to investigate the plausibility of attributing observed antenatal clinic declines to a female sex worker intervention in Karnataka state, India. AIDS 2008 22 : S149 64.
14. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007 18 : 352 358.
15. Kuo I., Ul-Hasan S., Galai N., Thomas D. L., Zafar T., Ahmed M. A. et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006 3 : 26.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2008: The State of the Drugs Problem in the European Union. Lisbon : EMCDDA 2008. Available at: http://www.emcdda.europa.eu/publications/annual- report/2008 (accessed 13 October 2008).
17. Health Protection Agency. Shooting Up. Infections among Injecting Drug Users in the United Kingdom 2007. London : Health Protection Agency 2008. Available at: http://www.hpa.org.uk/web/HPAweb & HPAwebStandard/HPAweb-C/ 1204186217321 (accessed 17 October 2008).
18. World Health Organization (WHO). WHO Drug Injecting Study - Phase II Operations Manual Version 4. des Jarlais D., Friedman S., Perlis T., editors. Geneva : WHO 2000. Available at : http://www.who.int/substance-abuse/activities/ en/WHODrugInjectionStudyOperationsManual.pdf (accessed 1 October 2008).
19. Matthews J. N., Altman D. G., Campbell M. J., Royston P. Analysis of serial measurements in medical research. BMJ 1990 300 : 230 235. (Pubitemid 20045528)
20. United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic Update. Geneva : UNAIDS 2008.
21. Calleja J. M., Walker N., Cuchi P., Lazzari S., Ghys P. D., Zacarias F. Status of the HIV/AIDS epidemic and methods to monitor it in the Latin America and Caribbean region. AIDS 2002 16 : S3 12.
22. Zocratto K. B., Caiaffa W. T., Proietti F. A., Carneiro-Proietti A. B., Mingoti S. A., Ribeiro GJ. HCV and HIV infection and co-infection: injecting drug use and sexual behavior, AjUDE-Brasil I Project. Cad Saude Publica 2006 22 : 839 848.
23. Massad E., Coutinho F. A., Yang H. M., De Carvalho H. B., Mesquita F., Burattini M. N. The basic reproduction ratio of HIV among intravenous drug users. Math Biosci 1994 123 : 227 247.
24. Garfein R. S., Monterroso E. R., Tong T. C., Vlahov D., Des Jarlais D. C., Selwyn P. et al. Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. J Urban Health 2004 81 : 260 267.
25. Battjes R. J., Pickens R. W., Brown L. S. Jr. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr Hum Retrovirol 1995 10 : 90 6.
26. Sutton A. J., Hope V. D., Mathei C., Mravcik V., Sebakova H., Vallejo F. et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat 2008 15 : 809 816.
27. United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) Working Group on Global HIV/AIDS and STI Surveillance. Guidelines for Second Generation HIV Surveillance: the Next Decade. Geneva : WHO, UNAIDS 2000 Available at: http://www.who.int/hiv/pub/surveillance/ (accessed 1 November 2008).
28. Reintjes R., Wiessing L. 2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg. Int J Public Health 2007 52 : 166 172.